NIMOTOP (nimodipine) is a calcium channel blocker indicated for patients with subarachnoid hemorrhage. It improves neurological outcome by relaxing cerebral smooth muscle vasculature and ...

Following diagnosis of postpartum cerebral angiopathy on postpartum day 10, nimodipine was initiated to treat the vasospasm, and the headache was treated with opioid analgesics and toradol ...

In the present study, the researchers used nimodipine, a blood-brain barrier-permeable CaV blocker, to decrease the contraction of capillaries induced by pericytes to increase cerebral blood flow ...

GRCE READ THE FULL GRCE RESEARCH REPORT We are initiating coverage of Grace Therapeutics, Inc. (NASDAQ:GRCE) with a valuation of $12.50 per share. This value is based on our estimates for the ...

Attorney General Keith Ellison celebrates settlements with two drug companies he accused of “scheming” to raise prices on ...

(Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease ...

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of ...

25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses ...

Nimodipine is initiated on admission in all patients with SAH for the prevention and treatment of vasospasm (Feigin, Rinkel, Algra, Vermeulen, & van Gijn, 1998; Rinkel et al., 2005). However ...